Compare Cardinal Health Inc (CAH) vs Rex Fang & Innovation Equity Premium Income ETF (FEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Rex Fang & Innovation Equity Premium Income ETF — how do they compare? Cardinal Health Inc trades at $230 (market cap $53.89B), while Rex Fang & Innovation Equity Premium Income ETF trades at $42. The key difference: Cardinal Health Inc pays a 0.89% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Cardinal Health Inc is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| CAH | FEPI | |
|---|---|---|
Market Cap | $53.89B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $239.71 | $49.54 |
52-Week Low | $146.04 | $38.13 |
Enterprise Value | $58.87B | — |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $41.98, down 1.65% with a bearish technical signal. The ETF employs an aggressive covered call strategy on concentrated AI and mega-cap tech holdings, generating weekly dividends averaging $0.21-0.22 recently. Technical indicators show bearish momentum with resistance at $43 and support at $42, while oscillators remain neutral. The fund's 25% yield attracts retail investors but comes with NAV erosion concerns during market downturns.
FEPI offers high income potential but faces structural limitations from its covered call strategy that caps upside during tech rallies. The concentrated portfolio of high-beta names amplifies downside risk, making it suitable for income-focused investors willing to accept limited capital appreciation. Recent transition to weekly distributions enhances compounding but doesn't address fundamental NAV erosion risks in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →
